FAQ on NanoViricides' Response to FDA COVID Booster Policy and Antiviral Strategy

What is NanoViricides’ response to the FDA’s updated COVID-19 booster shot policy?

NanoViricides’ President Dr. Anil Diwan applauded the FDA’s updated policy for focusing on high-risk groups and aligning with global standards, emphasizing the need for antiviral alternatives like NV-387.

Why is the FDA’s updated COVID-19 booster shot policy significant?

The policy’s shift to evidence-based guidance and focus on high-risk groups like seniors and those with co-morbidities highlights the importance of tailored approaches to public health and the need for alternative treatments.

What is NV-387 and how does it fit into NanoViricides’ strategy?

NV-387 is NanoViricides’ broad-spectrum antiviral drug candidate, intended to treat RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as part of the company’s strategy to reduce reliance on vaccines.

Who is involved in the development of NV-387?

NanoViricides is developing NV-387 in collaboration with TheraCour Pharma, Inc., under a Memorandum of Understanding that licenses technology for specific antiviral applications.

When can we expect NV-387 to enter Phase II human clinical trials?

NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials, but cannot project an exact date due to dependence on external collaborators and consultants.

Where can I find more information about NanoViricides and its drug candidates?

For more information about NanoViricides and its drug candidates, visit www.NanoViricides.com or the company’s newsroom at https://ibn.fm/NNVC.

What are the implications of NanoViricides’ antiviral strategy?

NanoViricides’ strategy to develop antiviral drugs like NV-387 could provide alternative treatments to vaccines, addressing the need for solutions in cases of limited booster uptake or broad public immunity.

How does NV-387 compare to other COVID-19 treatments?

NV-387 is a broad-spectrum antiviral drug that does not encapsulate remdesivir, unlike NV-CoV-2-R, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles, offering different mechanisms of action against COVID-19.

What should investors know about NanoViricides’ current focus?

Investors should note that NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials for various viral infections, with updates available in the company’s newsroom at https://ibn.fm/NNVC.